Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Bayer CropScience Q2...

    Bayer CropScience Q2 net profit down 25.13 percent

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-17T10:15:21+05:30  |  Updated On 17 Nov 2018 10:15 AM IST

    New Delhi: Agro-chemical firm Bayer CropScience has recently posted 25.13 per cent drop in its net profit at Rs 142.7 crore in the second quarter of the current fiscal on poor sales. Its net profit stood at Rs 190.6 crore in the same quarter previous year, according to a regulatory filing.


    Net income declined to Rs 1,104.1 crore during the July-September quarter of the current fiscal from Rs 1,232 crore in the year-ago.

    Expenses remained lower at Rs 897.5 crore as against Rs 954.6 crore in the said period.

    Commenting on the performance, Bayer CropScience chairman and managing director Richard van der Merwe said: "Sales were affected due to an erratic season marked by uneven rainfall and hailstorms that damaged standing crops in several parts of the country."

    Based on opportunities in the fruits and vegetable segment and in rice, the company expects a good performance in the third quarter and for the rest of the year, he added.

    The Board has approved in a meeting held Wednesday Duraiswami Narain's appointment as additional director of the company with effect from October 23, 2018, it said in a separate regulatory filing.

    In June, German chemical and pharma major Bayer AG announced the completion of the USD 63 billion mega-deal to acquire US-based biotech major Monsanto to create the world's biggest agrochemical and seed company.

    Bayer group is present in India since 1896 and it has two divisions cropscience and pharmaceutical. The group has one listed entity in India Bayer CropScience Ltd.
    Agro-chemicalBayerBayer CropScienceDuraiswami NarainMonsantoRichard van der MerweRs 142.7 crore
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok